Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01866540 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Response To Intranasal Influenza Vaccination

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 6, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2022 to Dec 31, 2025
    • Study completion date: Dec 31, 2022 to Dec 31, 2030
    v7
  2. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary and study completion dates: Dec 2022 to Dec 31, 2022
    • Start date: Oct 2012 to Oct 1, 2012
    v6
  3. Primary and study completion dates: Dec 2017 to Dec 2022
    • Publications: 1 to 9
    v5
  4. Trial status: Active, Not Recruiting to Enrolling by Invitation
    • Primary and study completion dates: Dec 2015 to Dec 2017
    v4
  5. Primary completion date: Mar 2015 to Dec 2015v3
  6. Enrollment target: 175 to 300v2 Show 6 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2014 to Mar 2015
    • Study completion date: Dec 2014 to Dec 2015
    • Eligibility criteria expanded, about 8 words
    • Study description expanded, about 6 words
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research during the last decade has focused on the kinetics of the systemic and local immune response to parenteral influenza vaccine in humans. The investigators have shown that normally high numbers of influenza specific antibody secreting cells (ASC) are present in the nasal mucosa of healthy adults but upon parenteral vaccination the numbers remain stable. However, a rapid transient increase in specific ASC is observed in the tonsils and peripheral blood after parenteral vaccination. In the tonsils, this is associated with a significant decrease in both naïve/effector (CD45RA+) and memory (CD45RO+) CD4+ cells upon vaccination. In this study the investigators will extend our work to investigate the characteristics of influenza-specific T- and B-cells induced locally and systemically after intranasal vaccination in man.
Trial Details
NCT Number NCT01866540
Lead Sponsor University of Bergen
Collaborators: Haukeland University Hospital
Conditions
(from sponsor)		 Tonsillitis, Hypertrophy
Related terms Hypertrophy, Influenza, Human, Tonsillitis
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov